JP2005530814A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005530814A5 JP2005530814A5 JP2004509678A JP2004509678A JP2005530814A5 JP 2005530814 A5 JP2005530814 A5 JP 2005530814A5 JP 2004509678 A JP2004509678 A JP 2004509678A JP 2004509678 A JP2004509678 A JP 2004509678A JP 2005530814 A5 JP2005530814 A5 JP 2005530814A5
- Authority
- JP
- Japan
- Prior art keywords
- disorder
- disease
- quinuclidine
- condition
- syndrome
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 18
- 201000010099 disease Diseases 0.000 claims 9
- 208000035475 disorder Diseases 0.000 claims 9
- 238000000034 method Methods 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- -1 trifluoromethoxy, cyano, amino Chemical group 0.000 claims 6
- 125000003545 alkoxy group Chemical group 0.000 claims 5
- 125000000217 alkyl group Chemical group 0.000 claims 5
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 3
- 206010010904 Convulsion Diseases 0.000 claims 3
- 206010049119 Emotional distress Diseases 0.000 claims 3
- 230000009429 distress Effects 0.000 claims 3
- 125000001475 halogen functional group Chemical group 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 239000001257 hydrogen Substances 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- UANSQQFYKHHDJM-KRWDZBQOSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]naphthalene-1-carboxamide Chemical compound C1=CC=C2C(C(N[C@@H]3C4CCN(CC4)C3)=O)=CC=CC2=C1 UANSQQFYKHHDJM-KRWDZBQOSA-N 0.000 claims 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000032841 Bulimia Diseases 0.000 claims 2
- 206010006550 Bulimia nervosa Diseases 0.000 claims 2
- 206010012735 Diarrhoea Diseases 0.000 claims 2
- 208000012661 Dyskinesia Diseases 0.000 claims 2
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 2
- 208000002193 Pain Diseases 0.000 claims 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims 2
- 230000006735 deficit Effects 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims 1
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 1
- MNEAITWEUWOECE-UHFFFAOYSA-N 1-(1-azabicyclo[2.2.2]octan-3-yl)-2-(trifluoromethyl)benzimidazole Chemical compound C1N(CC2)CCC2C1N1C2=CC=CC=C2N=C1C(F)(F)F MNEAITWEUWOECE-UHFFFAOYSA-N 0.000 claims 1
- ASZBYFJRDZMPKW-UHFFFAOYSA-N 1-(1-azabicyclo[2.2.2]octan-3-yl)-5-(trifluoromethyl)benzimidazole Chemical compound C1N(CC2)CCC2C1N1C2=CC=C(C(F)(F)F)C=C2N=C1 ASZBYFJRDZMPKW-UHFFFAOYSA-N 0.000 claims 1
- FHGRWVDBARLWBG-UHFFFAOYSA-N 1-(1-azabicyclo[2.2.2]octan-3-yl)benzimidazole Chemical compound C1=NC2=CC=CC=C2N1C(C1)C2CCN1CC2 FHGRWVDBARLWBG-UHFFFAOYSA-N 0.000 claims 1
- HZINIPZXUWIZML-UHFFFAOYSA-N 1-(1-azabicyclo[2.2.2]octan-3-yl)benzotriazole Chemical compound N1=NC2=CC=CC=C2N1C(C1)C2CCN1CC2 HZINIPZXUWIZML-UHFFFAOYSA-N 0.000 claims 1
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 claims 1
- 208000030507 AIDS Diseases 0.000 claims 1
- 208000002874 Acne Vulgaris Diseases 0.000 claims 1
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 208000000103 Anorexia Nervosa Diseases 0.000 claims 1
- 206010002660 Anoxia Diseases 0.000 claims 1
- 241000976983 Anoxia Species 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 1
- 206010003805 Autism Diseases 0.000 claims 1
- 208000020706 Autistic disease Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 108010009685 Cholinergic Receptors Proteins 0.000 claims 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims 1
- 208000019888 Circadian rhythm sleep disease Diseases 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
- 208000030814 Eating disease Diseases 0.000 claims 1
- 208000010228 Erectile Dysfunction Diseases 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 208000026097 Factitious disease Diseases 0.000 claims 1
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 1
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010021143 Hypoxia Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000001456 Jet Lag Syndrome Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 206010026749 Mania Diseases 0.000 claims 1
- 208000026139 Memory disease Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 241000208125 Nicotiana Species 0.000 claims 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000010886 Peripheral nerve injury Diseases 0.000 claims 1
- 208000004983 Phantom Limb Diseases 0.000 claims 1
- 206010056238 Phantom pain Diseases 0.000 claims 1
- 208000005374 Poisoning Diseases 0.000 claims 1
- 208000008348 Post-Concussion Syndrome Diseases 0.000 claims 1
- 208000005107 Premature Birth Diseases 0.000 claims 1
- 206010036590 Premature baby Diseases 0.000 claims 1
- 206010036618 Premenstrual syndrome Diseases 0.000 claims 1
- 206010036790 Productive cough Diseases 0.000 claims 1
- 206010052276 Pseudodementia Diseases 0.000 claims 1
- 208000028017 Psychotic disease Diseases 0.000 claims 1
- 208000022372 Reading disease Diseases 0.000 claims 1
- 208000034189 Sclerosis Diseases 0.000 claims 1
- 206010039966 Senile dementia Diseases 0.000 claims 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims 1
- 208000000323 Tourette Syndrome Diseases 0.000 claims 1
- 208000016620 Tourette disease Diseases 0.000 claims 1
- 208000025865 Ulcer Diseases 0.000 claims 1
- 102000034337 acetylcholine receptors Human genes 0.000 claims 1
- 206010000496 acne Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 230000007953 anoxia Effects 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 230000006793 arrhythmia Effects 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 1
- 229940049706 benzodiazepine Drugs 0.000 claims 1
- 208000028683 bipolar I disease Diseases 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 229960003920 cocaine Drugs 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 230000036461 convulsion Effects 0.000 claims 1
- 230000003111 delayed effect Effects 0.000 claims 1
- 229960002069 diamorphine Drugs 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 235000014632 disordered eating Nutrition 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 206010013932 dyslexia Diseases 0.000 claims 1
- 210000000750 endocrine system Anatomy 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 230000002650 habitual effect Effects 0.000 claims 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 1
- 208000013403 hyperactivity Diseases 0.000 claims 1
- 201000001881 impotence Diseases 0.000 claims 1
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 208000033915 jet lag type circadian rhythm sleep disease Diseases 0.000 claims 1
- 230000029849 luteinization Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 206010027175 memory impairment Diseases 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 229960005181 morphine Drugs 0.000 claims 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 230000002981 neuropathic effect Effects 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 229960002715 nicotine Drugs 0.000 claims 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 229940005483 opioid analgesics Drugs 0.000 claims 1
- 208000019906 panic disease Diseases 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 208000028591 pheochromocytoma Diseases 0.000 claims 1
- 231100000572 poisoning Toxicity 0.000 claims 1
- 230000000607 poisoning effect Effects 0.000 claims 1
- 230000002980 postoperative effect Effects 0.000 claims 1
- 206010036596 premature ejaculation Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 201000004700 rosacea Diseases 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 230000020341 sensory perception of pain Effects 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 208000020685 sleep-wake disease Diseases 0.000 claims 1
- 230000016160 smooth muscle contraction Effects 0.000 claims 1
- 208000024794 sputum Diseases 0.000 claims 1
- 210000003802 sputum Anatomy 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 230000001052 transient effect Effects 0.000 claims 1
Claims (14)
- R1及びR2が相互に独立して水素, C1-6アルキル, C1-6アルコキシ, ハロ, トリフルオロメチル, ヒドロキシ, シアノ, アミノ, ニトロ又はフェニルを示す、請求項1記載のキヌクリジン誘導体。
- R1及びR2のうちの一方が水素を示し、R1 及びR2 の他方がC1-6アルキル, C1-6アルコキシ, ハロ, トリフルオロメチル, ヒドロキシ, シアノ, アミノ, ニトロ又はフェニルを示す、請求項1記載のキヌクリジン誘導体。
- (±)-3-(1-ベンズイミダゾリル)-キヌクリジン;
(±)-3-(2-トリフルオロメチル-1-ベンズイミダゾリル)-キヌクリジン;
(±)-3-(5-トリフルオロメチル-1-ベンズイミダゾリル)-キヌクリジン、又は
(±)-3-(1-ベンゾトリアゾリル)-キヌクリジンである、請求項1記載のキヌクリジン誘導体、そのあらゆる対掌体又はその対掌体の混合物, 又はその薬学的に許容し得る塩, 又はそのアザ-オニウム-塩。 - 請求項1-4のいずれか1つに記載の3-置換されたキヌクリジン誘導体、又はそのあらゆる対掌体又はその対掌体の混合物, 又はその薬学的に許容し得る塩の治療上有効な量を、少なくとも1種の薬学的に許容し得るキャリヤー又は希釈剤と共に含有する薬学的調合物。
- ヒトを含めた哺乳類の疾患又は障害又は病態―――この疾患又は障害又は病態はコリン作動性レセプター及び(又は)モノアミンレセプターのモジュレーションに応答する―――の治療、予防又は緩和用薬学的調合物の製造に請求項1〜4のいずれか1つに記載の3-置換されたキヌクリジン誘導体又はその薬学的に許容し得る付加塩を使用する方法。
- 疾患、障害又は病態が中枢神経系に関連する、請求項6記載の使用する方法。
- 疾患、障害又は病態が、不安、認知障害、学習欠陥、記憶−欠損及び機能障害、アルツハイマー病、注意欠陥、注意欠陥多動性障害(ADHD)、パーキンソン病、ハンチングトン病、筋萎縮性側索硬化症、ジル・ド・ラ・ツレット症候群、精神病、うつ病、躁病、躁鬱病、統合失調症、強迫性障害(OCD)、パニック障害、摂食障害、たとえば神経性食欲不振、過食及び肥満、睡眠発作、侵害受容、AIDS-痴呆症、老人性痴呆症、神経障害、自閉症、読書障害、遅発性ジスキネジー、運動亢進症、癲癇、過食症、外傷後症候群、ソーシャルホビア、睡眠障害、仮性痴呆、ガンザー症候群、月経前症候群、遅い黄体期症候群、慢性疲労症候群、無言症、トリコチロマニア及び時差ボケである、請求項6記載の化合物の使用する方法。
- 疾患、障害又は病態が痙攣性障害、狭心症、早産、痙攣、下痢、喘息、癲癇、遅発性ジスキネジー、運動亢進症、早熟射精及び勃起障害を含む、平滑筋収縮に関連する、請求項6記載の使用する方法。
- 疾患、障害又は病態が内分泌系、たとえば甲状腺中毒症、褐色細胞腫、高血圧及び不整脈に関連する、請求項6記載の使用する方法。
- 疾患、障害又は病態が一時的無酸素症及び誘発された神経変性を含む神経変性疾患である、請求項6記載の使用する方法。
- 疾患、障害又は病態が炎症性皮膚障害、たとえばアクネ及びしゅさ、クーロン病、炎症性腸疾患、潰瘍性毛様体炎、及び下痢を含む、炎症障害である、請求項6記載の使用方法。
- 疾患、障害又は病態が、急性、慢性又は習慣的特徴の軽い、穏やかな又は激しい苦痛及び偏頭痛に起因する苦痛、術後の苦痛、幻想肢痛、神経障害性苦痛、慢性頭痛、中心性疼痛、 糖尿病性神経障害に, 治療後神経痛に又は末梢神経傷害に関連する苦痛である、請求項6記載の使用する方法。
- 疾患、障害又は病態が、ニコチン含有物質、たとえばタバコ、オピオイド、たとえばヘロイン、コカイン又はモルフィン、ベンゾジアゼピン又はベンゾジアゼピン様薬物、又はアルコールを含む依存性物質の使用中止に起因する禁断症状に関連する、請求項6記載の使用方法。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA200200834 | 2002-05-30 | ||
PCT/DK2003/000354 WO2003101987A1 (en) | 2002-05-30 | 2003-05-27 | 3-substituted quinuclidines and their use |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2005530814A JP2005530814A (ja) | 2005-10-13 |
JP2005530814A5 true JP2005530814A5 (ja) | 2006-07-06 |
Family
ID=29594980
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004509678A Withdrawn JP2005530814A (ja) | 2002-05-30 | 2003-05-27 | 3−置換されたキヌクリジン類及びその使用方法 |
Country Status (11)
Country | Link |
---|---|
US (2) | US7332507B2 (ja) |
EP (1) | EP1513839B1 (ja) |
JP (1) | JP2005530814A (ja) |
CN (1) | CN1656093A (ja) |
AT (1) | ATE334129T1 (ja) |
AU (1) | AU2003227522A1 (ja) |
CA (1) | CA2482639A1 (ja) |
DE (1) | DE60307102T2 (ja) |
MX (1) | MXPA04011858A (ja) |
NZ (1) | NZ536197A (ja) |
WO (1) | WO2003101987A1 (ja) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4890762B2 (ja) | 2002-09-25 | 2012-03-07 | メモリー・ファーマシューティカルズ・コーポレイション | インダゾール、ベンゾチアゾール、及びベンゾイソチアゾール、並びにそれらの調製及び使用 |
DE602004010299T2 (de) | 2003-12-22 | 2008-09-18 | Memory Pharmaceuticals Corp. | Indole, 1h-indazole, 1,2-benzisoxazole und 1,2-benzisothiazole und deren herstellung und anwendungen |
CN103724343A (zh) | 2004-03-25 | 2014-04-16 | 记忆药物公司 | 吲唑、苯并噻唑、苯并异噻唑、苯并异噁唑及其制备和用途 |
WO2006001894A1 (en) | 2004-04-22 | 2006-01-05 | Memory Pharmaceutical Corporation | Indoles, 1h-indazoles, 1,2-benzisoxazoles, 1,2-benzoisothiazoles, and preparation and uses thereof |
BRPI0510212A (pt) | 2004-05-07 | 2007-10-16 | Memory Pharm Corp | 1h-indazóis, benzotiazóis, 1,2 - benzoisoxazóis, 1,2-benzoisotiazóis, e cromonas e a preparação e usos dos mesmos |
PE20060373A1 (es) | 2004-06-24 | 2006-04-29 | Smithkline Beecham Corp | Derivados 3-piperidinil-7-carboxamida-indazol como inhibidores de la actividad cinasa de ikk2 |
MX2007007328A (es) | 2004-12-22 | 2007-07-25 | Memory Pharm Corp | Ligandos del receptor alfa-7 nicotinico y preparacion y sus usos. |
US8063071B2 (en) | 2007-10-31 | 2011-11-22 | GlaxoSmithKline, LLC | Chemical compounds |
AR065804A1 (es) | 2007-03-23 | 2009-07-01 | Smithkline Beecham Corp | Compuesto de indol carboxamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar un medicamento |
WO2010102968A1 (en) | 2009-03-10 | 2010-09-16 | Glaxo Group Limited | Indole derivatives as ikk2 inhibitors |
CN110845492B (zh) * | 2018-08-21 | 2022-05-13 | 鲁南制药集团股份有限公司 | 一种异丙托溴铵一水合物 |
CN110845491B (zh) * | 2018-08-21 | 2022-05-13 | 鲁南制药集团股份有限公司 | 一种异丙托溴铵晶体 |
CN113121522A (zh) * | 2019-12-30 | 2021-07-16 | 武汉先路医药科技股份有限公司 | 一种异丙托溴铵晶体及其制备方法 |
CN114306331B (zh) * | 2020-10-10 | 2023-07-18 | 远大生命科学(武汉)有限公司 | 戊乙奎醚在治疗或预防视力损伤性眼部疾病中的用途 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4009565A1 (de) * | 1990-03-24 | 1991-09-26 | Merck Patent Gmbh | Indolderivate |
SE9201478D0 (sv) | 1992-05-11 | 1992-05-11 | Kabi Pharmacia Ab | Heteroaromatic quinuclidinenes, their use and preparation |
SE9904176D0 (sv) | 1999-11-18 | 1999-11-18 | Astra Ab | New use |
DE10045112A1 (de) * | 2000-09-11 | 2002-03-21 | Merck Patent Gmbh | Verwendung von Indolderivaten zur Behandlung von Erkrankungen des zentralen Nervensystems |
AU2001296193B2 (en) * | 2000-10-20 | 2006-04-27 | Biovitrum Ab | 2-, 3-, 4-, or 5-substituted-N1-(benzensulfonyl)indoles and their use in therapy |
DE60132710T2 (de) * | 2000-12-01 | 2008-06-12 | Neurosearch A/S | 3-substituierte chinuclidine und ihre verwendung als nikotinische agonisten |
DE10121215A1 (de) * | 2001-04-30 | 2002-10-31 | Merck Patent Gmbh | Dihydro-imidazo[4,5-e]indol- und 7H-Pyrrolo[3,2-f]chinoxalin Derivate als nikotinische Acetylcholinrezeptor Liganden und/oder serotonerge Liganden |
DE10121217A1 (de) * | 2001-04-30 | 2002-10-31 | Merck Patent Gmbh | 6H-Oxazolo[4,5-e]indol-Derivate als nikotinische Acetylcholinrezeptor Liganden und/oder serotonerge Liganden |
-
2003
- 2003-05-27 WO PCT/DK2003/000354 patent/WO2003101987A1/en active IP Right Grant
- 2003-05-27 DE DE60307102T patent/DE60307102T2/de not_active Expired - Lifetime
- 2003-05-27 CN CNA038123258A patent/CN1656093A/zh active Pending
- 2003-05-27 JP JP2004509678A patent/JP2005530814A/ja not_active Withdrawn
- 2003-05-27 US US10/512,570 patent/US7332507B2/en not_active Expired - Fee Related
- 2003-05-27 CA CA002482639A patent/CA2482639A1/en not_active Abandoned
- 2003-05-27 MX MXPA04011858A patent/MXPA04011858A/es active IP Right Grant
- 2003-05-27 NZ NZ536197A patent/NZ536197A/en not_active IP Right Cessation
- 2003-05-27 AU AU2003227522A patent/AU2003227522A1/en not_active Abandoned
- 2003-05-27 EP EP03724901A patent/EP1513839B1/en not_active Expired - Lifetime
- 2003-05-27 AT AT03724901T patent/ATE334129T1/de not_active IP Right Cessation
-
2007
- 2007-12-20 US US12/004,022 patent/US20080132704A1/en not_active Abandoned
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2005524713A5 (ja) | ||
JP2005530814A5 (ja) | ||
JP2009538867A5 (ja) | ||
EP1866314B1 (en) | Novel diazabicyclic aryl derivatives and their medical use | |
EP1532144B1 (en) | quinuclidine derivatives and their use | |
JP2006508109A5 (ja) | ||
RU2008139481A (ru) | Новые 1,4-диаза-бицикло[3.2.2]нонил-оксадиазолильные производные и их медицинское применение | |
JP2007520525A5 (ja) | ||
JP2004538268A5 (ja) | ||
JP2009538866A5 (ja) | ||
JP2009538870A5 (ja) | ||
JP2010535738A (ja) | ニコチン性アセチルコリン受容体の調節物質として有用な新規1,2,3−トリアゾール誘導体 | |
JP2007530635A5 (ja) | ||
JP2009538869A5 (ja) | ||
JP2009537599A5 (ja) | ||
JP2008526706A5 (ja) | ||
JP2009526814A (ja) | 鏡像異性的に純粋なキヌクリジニルオキシピリダジン、及びニコチン性アセチルコリン受容体リガンドとしてのその使用 | |
JP2009526776A5 (ja) | ||
JP2005524712A5 (ja) | ||
RU2010114662A (ru) | Новые производные 1,4-диазабицикло(3.2.2)нонилпиримидина и их медицинское применение | |
JP2011530495A (ja) | ニコチン性アセチルコリン受容体のモジュレーターとして有用な新規のジフェニル1,2,3−トリアゾール誘導体 | |
RU2010135037A (ru) | Новые производные, 1,4-диазабицикло[3.2.2]нонилоксадиазолил, полезные в качестве модуляторов никотиновых ацетилхолиновых рецепторов | |
JP2009537598A5 (ja) | ||
JP2006503062A5 (ja) | ||
CN101044144A (zh) | 作为胆碱能配体的新的二氮杂双环芳基衍生物 |